Sunitinib Malate

Licensed by Pfizer Catalog No.S1042

Sunitinib Malate Chemical Structure

Molecular Weight(MW): 532.56

Sunitinib Malate is a multi-targeted RTK inhibitor targeting VEGFR2 (Flk-1) and PDGFRβ with IC50 of 80 nM and 2 nM in cell-free assays, and also inhibits c-Kit.

Size Price Stock Quantity  
In DMSO USD 191 In stock
USD 97 In stock
USD 147 In stock
USD 447 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 43 Publications

12 Customer Reviews

  • PDGF-AA induces Ezh2 expression and proliferation in juvenile islets but not in adult islets. Western immunoblots of indicated islet proteins from 3 week or 9 month-old WT islets 2 days after exposure to PDGF-AA alone, or PDGF-AA plus RTK inhibitors Sunitinib.

    Nature 2011 478(7369):349-55. Sunitinib Malate purchased from Selleck.

    Assessment of effects on human juvenile or adult islets after exposure to PDGF-AA (50 ng/ml) for 2 days, with or without Sunitinib (2 uM) or U0126 (10 uM)co-treatment. Average percentage of BrdU+ insulin+ cells was morphometry from sectioned islets immunostained for insulin (green), glucagon (white) and BrdU (red). n = 3-6 independent experiments.

    Nature 2011 478(7369):349-55. Sunitinib Malate purchased from Selleck.

  • Combinational treatment of kinase inhibitors induces the similar phenotype produced by PP1. All images are lateral view with dorsal to the top and anterior to the left. The combinational treatment of Dasatinib (D) or U0126 (U) with Sunitinib (SU),PTK787 (PTK), or ZM323881 (Z) resulted in the shrinkage of dorsal aorta.

    Cell Res 2011 21, 1080-1087. Sunitinib Malate purchased from Selleck.

    A, Tumor growth curves from the initial sunitinib drug trials, with endpoint set at 1,300 mm3 (mean ± SEM). Measurements began one week after tumor inoculation and on the day sunitinib treatment began. Subsequent experimental endpoints were set on the basis of these growth curves and their intersections with this data are shown. B, Histogram plot showing the distribution of tumor sizes at day 8 of treatment. Sunitinib-treated tumors exceeding 250 mm3 in size were identified as falling into the nonresponsive cohort. Sunitinib treatment significantly retards growth of responsive tumors.

    Cancer Res, 2017, 77(4):1008-1020 . Sunitinib Malate purchased from Selleck.

  • Sunitinib decreases FLT-3 and RET phosphor ylation but increases ERK phosphorylation in a time-dependent manner. H295R and SW13 cells were treated with sunitinib (10 nM) for various time points as indi-cated. Cell lysates were prepared and phospho-FLT-3, RET, and ERK levels were monitored by Western Blot-ting. Re-probing against FLT-3, RET, and ERK was done to ensure equal protein loading.

    Surgery 2012 152, 1045-50. Sunitinib Malate purchased from Selleck.

    Sunitinib or PD98059 decreases cell proliferation in a dose-dependent manner. H295R and SW13 cells were treated with various concentration of sunitinib or PD98059 for 48 hours as indicated. Treated cells were subjected to the MTS proliferation assay. Similar experiments were repeated 3 times. Histograms represent relative % of OD490 nm absorbance (* P < .05). All data are relative multiples of expression compared with untreated cells. The data are representative of three experiments and are expressed as the mean ?SE.

    Surgery 2012 152, 1045-50. Sunitinib Malate purchased from Selleck.

  • Autophagic activation in sunitinib- and sorafenib- but not AZD6244-treated cells. Medullary thyroid cancer-1.1 (MTC-1.1; A) and TT ( B) cells were treated with dimethyl sulfoxide (DMSO), sunitinib (50 nM), sorafenib (10 nM), AZD6244 (30 nM), or everolimus (20 nM) for 48 hours. Cell lysates were prepared, and light chain 3 (LC3)-I and -II cleaved caspase-3 protein levels were monitored by Western blotting. Reprobing against actin was per formed to ensure equal protein loading. ( C ) MTC-1.1 and TT cells were transiently transfected with autophagy protein 5 (Atg-5) small inter fering RNA. Transfection with scrambled small inter fering RNA was used as a control. After transfection, cells with and without Atg-5 knockdown were exposed to DMSO or 20 nM of everolimus for 48 hours. Cell lysates were pre- pared and LC3-I and -II protein expression levels were monitored by Western blotting. Reprobing against Atg-5 was per formed to monitor Atg-5 knockdown efficiency. Reprobing against actin was per formed to ensure equal protein.

    Surgery 2012 152, 1142-9. Sunitinib Malate purchased from Selleck.

    Autophagy inhibition blocks the antiproliferative effects of sunitinib and sorafenib but not AZD6244. Medullary thyroid cancer–1.1 (MTC-1.1) and TT cells were transfected transiently with scrambled or autophagy protein 5 (Atg-5) small inter fering RNA. After transfection, cells with and without Atg-5 knockdown were exposed to sunitinib (50 nM), sorafenib (10 nM), and AZD6244 (30 nM) for 48 hours. Treated cells were subjected to a 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium proliferation assay. Similar experiments were repeated 3 times. Histograms represent the relative percent of OD490 nM absorbance. The asterisk indicates significance versus scrambled small inter fering RNA–treated control ( P < .05). All data are relative multiples of expression compared to untreated cells. The data are representative of 3 experiments and are expressed as the mean ± the standard error.

    Surgery 2012 152, 1142-9. Sunitinib Malate purchased from Selleck.

  • Sunitinib limits the colonial growth of HT-29 by downregulating HIF-1a. (A) The number and size of colonies formed in soft agar. The numbers of small colonies (<50 μm diameter) were not different among conditions of a serial concentration of sunitinib. On the contrary, large colonies (>50 μm diameter) disappeared after incubation with sunitinib. Each point represents the mean and SD from four separate experiments. (B) HIF-1a expression and hypoxia within HT-29 colony. After colonies grew for 4 weeks, HIF-1a and hypoxia were visualized by immunofluoroscence staining. Bar = 20 μm.

    Biochem Bioph Res Co 2010 398, 205–211. Sunitinib Malate purchased from Selleck.

    2. Sunitinib downregulates HIF-1a. (A) Dose-dependent repression of HIF-1a protein level by sunitinib in HT-29. HT-29 cells were incubated under normoxic (N) or hypoxic (H) conditions in the presence of sunitinib for 24 h. HIF-1a and ARNT proteins in total cell lysates were analyzed by Western blotting. (B) Sunitinib attenuates the hypoxic induction of HIF-1 target genes. RNAs were isolated from HT-29 cells subjected to normoxia (N) or hypoxia (H) in the presence of sunitinib for 16 h. The mRNAs of HIF-1a and its target genes were analyzed by RT-PCR and autoradiography. PGK1 indicates phosphoglycerate kinase 1; PDK1, pyruvate dyhydrogenase kinase 1; CAIX, carbonic anhydrase IX. (C) Sunitinib-induced HIF-1 inhibition. Epo-enhancer and b- galactosidase reporter plasmids were co-transfected into HEK293 cells. After 16 h incubation, luciferase and b-galactosidase activities were measured. *P < .05 versus the hypoxic control.

     

     

    Biochem Bioph Res Co 2010 398, 205–211. Sunitinib Malate purchased from Selleck.

  • Sunitinib inhibits 50-UTR-dependent translation of HIF-1a. (A) 50 cap-dependent translational activity of HIF-1a. The luciferase reporter plasmid contains the HIF-1a 50-UTR segment between the tk promoter and the luciferase gene. HT-29 cells were co-transfected with the reporter plasmid (8 lg per 100-mm dish) and the b-gal plasmid (4 μg). After 16 h incubation under normoxic or hypoxic conditions with sunitinib, cells were lysed and subjected to luciferase assay. *P < .05 versus the hypoxic control. (B) IRES-dependent translational activity of HIF-1a. The luciferase reporter plasmid contains the HIF-1a 50-UTR segment between the GFP gene and the luciferase gene. HT-29 cells were co-transfected with the reporter plasmid (8 μg) and the b-gal plasmid (4 μg). *P < .05 versus the hypoxic control. (C) Sunitinib inhibits phosphorylation of Akt. After 8 h incubation under hypoxic condition with sunitinib, HT-29 cells were lysed and subjected to Western blotting. (D) Sunitinib suppresses HIF-1a in VHL-null RCC4 cells. VHL (-/-) RCC4 cells were incubated under normoxic conditions sunitinib for 8 h, and HIF-1a in total cell lysates was analyzed by Western blotting.

     

     

    Biochem Bioph Res Co 2010 398, 205–211. Sunitinib Malate purchased from Selleck.

    Experimental layout for VEGF signaling blocking and LCMV infection in WT mice. Mice received two injections on day 0 and 3 p.i. of Abs as described in Material and Methods, or daily gavage of the VEGFR/PDGFR-inhibitor sunitinib. Inguinal LN volume on day 0 (D0) or day 8 (D8) p.i. after treatment of mice with control Ig or anti-VEGFR2, anti-VEGF-A Abs or sunitinib. Pooled from 1-2 independent experiments with 3-5 mice per treatment. D. Total HEV length on day 0 (D0) or day 8 (D8) p.i. as in C. No significant difference was found in C and D between day 8 control Ig and Ab- or inhibitor-treated values (One-way ANOVA).

    AACR Sunitinib Malate purchased from Selleck.

Purity & Quality Control

Choose Selective PDGFR Inhibitors

Biological Activity

Description Sunitinib Malate is a multi-targeted RTK inhibitor targeting VEGFR2 (Flk-1) and PDGFRβ with IC50 of 80 nM and 2 nM in cell-free assays, and also inhibits c-Kit.
Targets
Kit [1]
(Cell-free assay)
FLT3 [1]
(Cell-free assay)
PDGFRβ [1]
(Cell-free assay)
VEGFR2 [1]
(Cell-free assay)
2 nM 80 nM
In vitro

Sunitinib also potently inhibits Kit and FLT-3. [1] Sunitinib is a potent ATP-competitive inhibitor of VEGFR2 (Flk1) and PDGFRβ with Ki of 9 nM and 8 nM, respectively, displaying >10-fold higher selectivity for VEGFR2 and PDGFR than FGFR-1, EGFR, Cdk2, Met, IGFR-1, Abl, and src. In serum-starved NIH-3T3 cells expressing VEGFR2 or PDGFRβ, Sunitinib inhibits VEGF-dependent VEGFR2 phosphorylation and PDGF-dependent PDGFRβ phosphorylation with IC50 of 10 nM and 10 nM, respectively. Sunitinib inhibits VEGF-induced proliferation of serum-starved HUVECs with IC50 of 40 nM, and inhibits PDGF-induced proliferation of NIH-3T3 cells overexpressing PDGFRβ or PDGFRα with IC50 of 39 nM and 69 nM, respectively. [2] Sunitinib inhibits phosphorylation of wild-type FLT3, FLT3-ITD, and FLT3-Asp835 with IC50 of 250 nM, 50 nM, and 30 nM, respectively. Sunitinib inhibits the proliferation of MV4;11 and OC1-AML5 cells with IC50 of 8 nM and 14 nM, respectively, and induces apoptosis in a dose-dependent manner. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
3T3 NYHUTIdSU2mwYYPlJGF{e2G7 MWLJcohq[mm2aX;uJI9nKFCGR1[tbY5lfWOnZDDCdoRWKGmwY3;ydI9z[XSrb36ge4l1cCCLQ{WwJI9nKDBwMEC3JO69VQ>? MXWxNlY1PjBzOR?=
3T3 M1jqVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkP2TY5pcWKrdHnvckBw\iCSbHH0[YxmfC2mZYLpeoVlKGe{b4f0bEBn[WO2b4KgbY5lfWOnZDCzWFMh[2WubDDwdo9tcW[ncnH0bY9vKHerdHigTWM2OCCxZjCwMlAyKM7:TR?= NYTVbGM4OTJ4NE[wNVk>
3T3 NGXvRnlHfW6ldHnvckBCe3OjeR?= MknhTY5pcWKrdHnvckBw\iCYYYPjeYxieiCnbnTveIhmdGmjbDDndo94fGhiZnHjeI9zKHKnY3XweI9zKHerdHigTWM2OCCxZjCwMlA2KM7:TR?= MXKxNlY1PjBzOR?=
3T3 MmPoT4lv[XOnIFHzd4F6 NWn2SJNOOjBibXnu MmPjSG1UVw>? NX;iclF{S2WubIXsZZIhcW6qaXLpeIlwdiCxZjDWSWdHKGmwZIXj[YQhcHWvYX6gT2RTKHCqb4PwbI9zgWyjdHnvckB4cXSqIFnDOVAhd2ZiMD6wNlIh|ryP M4nzWlE3OTZ{MEC4
NIH3T3 MVLLbY5ie2ViQYPzZZk> Mn7ZNlAhdWmw MlvuSG1UVw>? MVnpcohq[mm2IHj1cYFvKEuGUjDrbY5ie2ViZYjwdoV{e2WmIIfpeIghUUN3MDDv[kAxNjBzODFOwG0> M4W2UlE3OTZ{MEC4
A549 MWPGeY5kfGmxbjDBd5NigQ>? NHzndoNFVVOR NFG3UGdKdmirYnn0bY9vKG:oIHOtUYV1KGSncHXu[IVvfCCKR1[tbY5lfWOnZDDoeY1idiCDNUS5JINmdGxibXnndoF1cW:wIIfpeIghUUN3MDDv[kAzKM7:TR?= MX6xPFQ{PDF2NR?=
DU145 MnTISpVv[3Srb36gRZN{[Xl? MoTkSG1UVw>? NIHpdnhKdmirYnn0bY9vKG:oIHOtUYV1KGSncHXu[IVvfCCKR1[tbY5lfWOnZDDoeY1idiCGVUG0OUBk\WyuIIPjZZR1\XKrbnege4l1cCCLQ{WwJI9nKDFyIN88US=> NXPSTYo6OTh2M{SxOFU>
KB3-1 NHWzcmxEgXSxdH;4bYMhSXO|YYm= NYHBV|cxPzJiaB?= MmPHSG1UVw>? MVTDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDQMYdxNW6nZ3H0bZZmKEuELUOtNUBk\WyuczD3bZRpKEmFNUCgc4YhOi5|IN88US=> M{Sxc|E6Ozl5M{Ky
KBV1 NXHMenZbS3m2b4TvfIlkKEG|c3H5 NHL5[VM4OiCq M{nWT2ROW09? M1PocmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHAu\2y7Y3;wdo91\WmwLXX4dJJme3OrbnegT2JXOSClZXzsd{B4cXSqIFnDOVAhd2ZiND6xJO69VQ>? MVSxPVM6PzN{Mh?=
A375 MljRR5l1d3SxeHnjJGF{e2G7 NUfDfnV1PzJiaB?= M1T3cmROW09? M1S4UWlEPTB;NT60JO69VQ>? MUexPVY2PDRyOB?=
RS4-11 NIf5UoxHfW6ldHnvckBCe3OjeR?= NYK2OmszOiCq MkDvTY5pcWKrdHnvckBw\iCITGSzJIF2fG:yaH;zdIhwenmuYYTpc44hf2m2aDDJR|UxKG:oIECuNFA6QSEQvF2= M4HZRlE6PjV2NEC4
RS4-11 NUH4XHBITnWwY4Tpc44hSXO|YYm= NUnkPJRIOiCq MmLlTY5pcWKrdHnvckBw\iCITGSzJGlVTCCvdYThcpQh[XW2b4Doc5NxcG:{eXzheIlwdiC5aYToJGlEPTBib3[gNE4xOzRizszN NUDlO3FIOTl4NUS0NFg>
Sf9 NVrONm5kU2mwYYPlJGF{e2G7 NWDSfWZ2OzBibXnu Mn7wTY5pcWKrdHnvckBw\iCJU2SteIFo\2WmIG\FS2ZTKGW6cILld5Nm\CC5aYToJGlEPTBib3[gNE4yQDVizszN MXKxPVg2PDB3MR?=
Ba/F3 M2\UUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3hVm44OiCq MmW3TWM2OD1zLkKg{txO NV3QSXpWOjBzMUewNFQ>
BaPTC2 M2fQeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIniW5M4OiCq M2DsbmlEPTB;MD6yNkDPxE1? MYSyNFEyPzByNB?=
Sf9 M{fGR2Z2dmO2aX;uJGF{e2G7 MV[xJIg> NEjPb5ZFVVOR MoLJTY5pcWKrdHnvckBw\iCqdX3hckBz\WOxbXLpcoFvfCCKaYOteIFo\2WmIGLFWEBmgHC{ZYPz[YQhf2m2aDDJR|UxKG:oIEGuN{DPxE1? MWSyNFEyPzByNB?=
H4 M3L1dmN6fG:2b4jpZ{BCe3OjeR?= MXuxNEDPxE1? NXrsS3lpXG:6aXPpeJkhcW5iaIXtZY4hUDRiY3XscJM> MlW2NlA{PTB6ME[=
SF-539 NV;QeGN[U2mwYYPlJGF{e2G7 NIXLPGw{OzNizszN M4fZZlYxKG2rbh?= MmrPSG1UVw>? MkjZTY5pcWKrdHnvckBw\iCSRFfGVoJmfGFicHjvd5Bpd3K7bHH0bY9vKHerdHigTWM2OCCxZjCxNk4zKM7:TR?= NUDmU3ExOjB2MEO3NFA>
U251 MV\LbY5ie2ViQYPzZZk> NGjxVmE{OzNizszN MkXiOlAhdWmw MoD4SG1UVw>? MmX0TY5pcWKrdHnvckBw\iCYRVfGVlIheGixc4Doc5J6dGG2aX;uJJdqfGhiSVO1NEBw\iBzOD65JO69VQ>? M1jOPVIxPDB|N{Cw
A431 MkCxT4lv[XOnIFHzd4F6 NWXCN2l3UW6qaXLpeIlwdiCxZjDQSGdHWmKndHGg[ZhxemW|c3XkJJdqfGhiSVO1NEBw\iBzMj6yJO69VQ>? M1P4TFIxPTV6MEey
A431 NInoVZdMcW6jc3WgRZN{[Xl? NHTtfllKdmirYnn0bY9vKG:oIG\FS2ZTOiCneIDy[ZN{\WRid3n0bEBKSzVyIH;mJFE5NjlizszN MnrENlA2PThyN{K=
HepG2 NFm1NpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPS[mdiPzJiaB?= NIKxV3pKSzVyPUOuPFEh|ryP MnPINlA2PzB3Mk[=
Kasumi-1 M17PcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHYO3M4OiCq NWnQS3JiUUN3ME2wMlAyPiEQvF2= NUPIS3lmOjB3N{C1NlY>
RS4-11 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXO3NkBp MV7JR|UxRTFizszN MYiyNFU4ODV{Nh?=
THP1 MnfMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLXWYVvPzJiaB?= M2HvTGlEPTB;MD61JO69VQ>? NFPufoIzODV5MEWyOi=>
Kasumi-1 M2PrOWZ2dmO2aX;uJGF{e2G7 MmX3TY5pcWKrdHnvckBw\iClLVvpeEBifXSxcHjvd5Bpd3K7bHH0bY9vKHerdHigTWM2OCCxZjCwMlAyPSEQvF2= NXPafmEyOjB6M{OwN|k>
A549 M1zuXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTmNVYhcA>? MYnBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6|dDDoeY1idiCDNUS5JINmdGy| MX:yNVQ2ODR4Mx?=
HL60 NF;v[2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{W4NlE3KGh? M1vlSGFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjMOlAh[2WubIO= M3\pXlIyPDVyNE[z
HUVEC M3SwWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTWNlFCOTZiaB?= NX7FXHY3UW6qaXLpeIlwdiCxZjDWSWdHNWmwZIXj[YQh[2WubDDwdo9tcW[ncnH0bY9vKHerdHigTWM2OCCxZjCyMlc2KM7:TR?= NETrVpYzOTR3MES2Ny=>
HUVEC MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\6d4JLOTZiaB?= MWXJcohq[mm2aX;uJI9nKGKIR1[tbY5lfWOnZDDj[YxtKHC{b3zp[oVz[XSrb36ge4l1cCCLQ{WwJI9nKDRwMESg{txO M3HWbVIyPDVyNE[z
IM9 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXONVYhcA>? NVHBXI15SW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gTW06KGOnbHzz MmHLNlE1PTB2NkO=
K562 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlroNVYhcA>? MWjBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6|dDDoeY1idiCNNU[yJINmdGy| NWHoPG1qOjF2NUC0OlM>
MDA-MB-231 NHPNNWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVTiSnlYOTZiaB?= NWns[FA6SW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gUWRCNU2ELUKzNUBk\Wyucx?= NW\yZ2tNOjF2NUC0OlM>
H460 NHzseXdEgXSxdH;4bYMhSXO|YYm= MonpO|IhcA>? MVfJR|UxRTJwNzFOwG0> NGPWS3ozOTZ{MUi4NC=>
SMMC7721 NYP2[2dtS3m2b4TvfIlkKEG|c3H5 NH;5c2g4OiCq NE\oRoFKSzVyPU[uOFch|ryP NF62e4YzOTZ{MUi4NC=>
WI38 NH7HdIlEgXSxdH;4bYMhSXO|YYm= MUe3NkBp M{\oWGlEPTB;OD61OkDPxE1? NYnxfpNQOjF4MkG4PFA>
HEK293 MmHTT4lv[XOnIFHzd4F6 NUT2RYFOOTByIH7N MVqxJIg> NVLBTlF[\G:nczDuc5QhcW6qaXLpeEBXTUeILXnu[JVk\WRiYYX0c5Bpd3OyaH;yfYxifGmxbjDv[kB1gXKxc3nu[UAyOTd3IILld4llfWVib36gWmVITlJ{IHX4dJJme3OnZDDpckBJTUt{OUOgZ4VtdHN? M{e5VlIyQDh3Mki3
HUVEC NV7hSoVtTnWwY4Tpc44hSXO|YYm= NEPnc3MyKM7:TR?= MWqyOEBp MXrBcpRq[W6paX;n[Y5q[yCjY4Tpeol1gSCjc4Pld5Nm\CCjczDk[YNz\WG|ZTDpckBXTUeILXnu[JVk\WRiY3XscEBucWe{YYTpc44> M3fDZ|IyQTZ|M{C1
HUVEC MoHVSpVv[3Srb36gRZN{[Xl? NHrBOmUyKM7:TR?= NYHvPWcxOSCq NI[1bWJKdmirYnn0bY9vKG:oIFXST{BxcG:|cHjvdplt[XSrb36gZZQhXGi{MkCyM3R6ejJyNDDpckBXTUeILYP0bY12dGG2ZXSgTHVXTUN? M2LtS|IyQTZ|M{C1
HUVEC MV7GeY5kfGmxbjDBd5NigQ>? MV[xJO69VQ>? MYCxJIg> NGLmN4NKdmirYnn0bY9vKG:oIHXOU3MheGixc4Doc5J6dGG2aX;uJIF1KFOncj2xNVczKGmwIG\FS2Yue3SrbYXsZZRm\CCKVW\FRy=> M{GwWVIyQTZ|M{C1
HUVEC M4DpfmtqdmG|ZTDBd5NigQ>? MoD4NUDPxE1? MW[xJIg> NXPLRWNxUW6qaXLpeIlwdiCxZjDWSWdHWjJicHjvd5Bpd3K7bHH0bY9vKGG2IIT5dk0yOTd3IHnuJHZGT0Zvc4TpcZVt[XSnZDDIWXZGSw>? M3PmV|IyQTZ|M{C1
HUVEC MoG1SpVv[3Srb36gRZN{[Xl? M3\yO|Eh|ryP NI\JT|UyKGh? MXvkc4V{KG6xdDDpcohq[mm2IFHLWEBxcG:|cHjvdplt[XSrb36gZZQhW2W{LUS3N{BqdiCYRVfGMZN1cW23bHH0[YQhUFWYRVO= NF3HWY4zOTl4M{OwOS=>
HL60 M{jZXWN6fG:2b4jpZ{BCe3OjeR?= MVO1NEDPxE1? MoLTOFghcA>? NEnX[YJFVVOR NGfTUoNKSzVyPUG1MlUh|ryP NFrybZkzOjBzOUG4PC=>
K562 MULDfZRwfG:6aXOgRZN{[Xl? MnrQOVAh|ryP MkDLOFghcA>? MljnSG1UVw>? NFHkTldKSzVyPUKxMlkh|ryP MmnCNlIxOTlzOEi=
PC3 NIDwS3ZEgXSxdH;4bYMhSXO|YYm= Ml3zOVAh|ryP M{Dl[VQ5KGh? NYTQTJJMTE2VTx?= NXzHboRKUUN3ME2yOU4yKM7:TR?= NFra[XYzOjBzOUG4PC=>
SF-539 M3nyUmtqdmG|ZTDBd5NigQ>? NGrqbmY{OzNizszN NWTBNnU6PjBibXnu MkDITY5pcWKrdHnvckBw\iCSRFfGVoJmfGFidInyc5NqdmVia3nuZZNmKGGldHn2bZR6KGmwIGDES2YuSkJvc4TpcZVt[XSnZDDoeY1idiCVRj21N|kh[2WubIOge4l1cCCLQ{WwJI9nKDF{LkKg{txO M2\0TlIzOjB2N{Sx
HAEC MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXexNFAh|ryP NUG0ZohvPzJiaB?= M1Tp[WFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFHFR{Bk\WyuczDlfJBz\XO|aX7nJHZGT0[UIIfpeIghUUN3MDDv[kAxNjFizszN MYeyNlQ1PDZ5OR?=
HT-29 NV65OZhUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7RfHcyODBizszN MUe3NkBp NWi1[oVLSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIWE0zQSClZXzsd{BmgHC{ZYPzbY5oKF[HR1\SJJdqfGhiSVO1NEBw\iByLkOzJO69VQ>? NE\VOI8zOjR2NE[3PS=>
MV4-11 M2XXWGN6fG:2b4jpZ{BCe3OjeR?= M4O1XFczKGh? MoDJTWM2OD1yLkCwN{DPxE1? NYf1ZoxDOjJ2NUK1NVg>
HepG2 MYPDfZRwfG:6aXOgRZN{[Xl? M4PUNFQ5KGh? NVTkXmZ6UUN3ME2xN{4zPCEQvF2= MUSyNlQ5OzZyOB?=
PC9 MmXUR5l1d3SxeHnjJGF{e2G7 MV:0PEBp MmrkTWM2OD1zMD65O{DPxE1? M3X4PVIzPDh|NkC4
CAKI-1 M4jqZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fsd|ExOCEQvF2= MXS0PEBp NFLVUZpFVVOR NHzLNJRIUTVyPUCuOlMh|ryP MonYNlI2PjB4Mke=
EKVX Mm\CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzzb2Z5OTByIN88US=> Mnn1OFghcA>? MkfaSG1UVw>? M2GyWGdKPTB;Nz65JO69VQ>? M3ftc|IzPTZyNkK3
MCF7 NXLMZpJFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzENVAxKM7:TR?= NGC1ZW01QCCq MVLEUXNQ MX\HTVUyRTJizszN Mmr6NlI2PjB4Mke=
MDA-MB-435 NX\LbplzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml21NVAxKM7:TR?= MVW0PEBp MkS2SG1UVw>? MlK2S2k2Oj1{IN88US=> NGfEO2IzOjV4ME[yOy=>
OVCAR3 M3:2bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3K4OVExOCEQvF2= NFjQO3Y1QCCq MkLpSG1UVw>? MkLGS2k2Oz1|LkKg{txO MlrlNlI2PjB4Mke=
SNB19 M1XLTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX6xNFAh|ryP MVq0PEBp NGPYeVVFVVOR NHPtcmRIUTV2PUGwJO69VQ>? NIXUc4kzOjV4ME[yOy=>
SW620 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYqxNFAh|ryP M334e|Q5KGh? NWHK[IdUTE2VTx?= M3W4bGdKPTV;MT6zJO69VQ>? MYKyNlU3ODZ{Nx?=
TK10 MlnjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnX3NVAxKM7:TR?= NUDDSJlXPDhiaB?= MkHtSG1UVw>? MmPUS2k2Pj14LkOg{txO MWOyNlU3ODZ{Nx?=
UACC257 M4DyOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPQTmsyODBizszN NV\jVHFkPDhiaB?= NF7vc3RFVVOR NHW1XoVIUTV5PUSg{txO M1TYT|IzPTZyNkK3
HAEC NH;mV2FEgXSxdH;4bYMhSXO|YYm= NYLO[HNQOTByIN88US=> MWe3NkBp MlTVSG1UVw>? NGrySpNEgXSxdH;4bYNqfHliYXfhbY5{fCCYRVfGVkBmgHC{ZYPzbY5oKEiDRVOge4l1cCCLQ{WwJI9nKDBwMTFOwG0> M1\oPFI{OTNzNUSx
HT-29 NEDxUWxEgXSxdH;4bYMhSXO|YYm= M4HGc|ExOCEQvF2= MlLDO|IhcA>? NYHPcnduTE2VTx?= MkLxR5l1d3SxeHnjbZR6KGGpYXnud5QhXkWJRmKg[ZhxemW|c3nu[{BpfW2jbjDIWE0zQSClZXzsd{B4cXSqIFnDOVAhd2ZiMD6zN{DPxE1? NY[2dFBOOjNzM{G1OFE>
HCT116 M1T0XmZ2dmO2aX;uJGF{e2G7 MYeyOEBp MmPzSG1UVw>? NFnzcHpCdnSrbXnndoF1d3K7IHHjeIl3cXS7IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiY3XscEBucWe{YYTpc44> MX[yN|E2OzJyMB?=
HUVEC NV3VflVlTnWwY4Tpc44hSXO|YYm= NWT4XHlDOiEQvF2= NFrKSG4yQCCq NWTTfY57TE2VTx?= MYPBcpRq[W6paX;n[Y5q[yCjY4Tpeol1gSCrbjDIWXZGS3NidX7k[ZIhcHmyb4jpZ{Bkd26maYTpc44h[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kB1fWKnIH\vdo1ifGmxbh?= M13nd|I{OTV|MkCw
ACHN Ml3nR5l1d3SxeHnjJGF{e2G7 NXm0S5FWPiCm M{TYT2lEPTB;Mj61JO69VQ>? MVOyN|M3ODFyNB?=
A498 MkDxR5l1d3SxeHnjJGF{e2G7 MmPvNVAxKM7:TR?= MWi3NkBp M365WWROW09? MnriTWM2OD12LkOg{txO MnfINlM1QDl4Mk[=
HUVEC NILk[mtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTVN{DPxE1? MW[yOEBp MonUSG1UVw>? M2XaNWFvfGmjbnfpc4dmdmmlIHHjeIl3cXS7IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiVlXHSk1qdmS3Y3XkJJR2[mViZn;ycYF1cW:wIIfpeIghTUN3MDDv[kAxNjZ2NTFOwG0> NGfwdnMzOzV6M{mxNS=>
HUVEC M33lZ2tqdmG|ZTDBd5NigQ>? M{f3eFIxOCEQvF2= MlS2SG1UVw>? M{TzNGlvcGmkaYTpc44hd2ZiVlXHSnIzKHCqb4PwbI9zgWyjdHnvckBqdiCpcn;3eIgh\mGldH;yMZN1cW23bHH0[YQhUFWYRVO= M33UfVI{PTh|OUGx
HUVEC NXfCVotOU2mwYYPlJGF{e2G7 M4fXeVIxOCEQvF2= MofLSG1UVw>? Moq3TY5pcWKrdHnvckBw\iCYRVfGVlEheGixc4Doc5J6dGG2aX;uJIlvKGe{b4f0bEBn[WO2b4Ktd5RqdXWuYYTl[EBJXV[HQx?= M1ThdFI{PTh|OUGx
A549 NWfOZnNPS3m2b4TvfIlkKEG|c3H5 M1PPN|czKGh? NYjIV4xWTE2VTx?= NF\vdXpKSzVyPUKuOFQh|ryP NV[yToZYOjN4MEK0OFE>
HCT116 MX\DfZRwfG:6aXOgRZN{[Xl? MUe3NkBp NVHodHlWTE2VTx?= M1u0TGlEPTB;ND63NUDPxE1? MX6yN|YxOjR2MR?=
MCF7 Mn;4R5l1d3SxeHnjJGF{e2G7 M1nPO|czKGh? MUDEUXNQ M1rqU2lEPTB;Nj6yPUDPxE1? NHnNeYszOzZyMkS0NS=>
BGC M3LGWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\GO|IhcA>? M2HiW2ROW09? NFfkWpZKSzVyPUSuO|gh|ryP M1[1W|I{QTl7MESw
BxPC3 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVO4eJZtPzJiaB?= NYDzVJFPTE2VTx?= NIT0fINKSzVyPUOuOlMh|ryP MYiyN|k6QTB2MB?=
HT-29 M3jJbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVzBdlliPzJiaB?= MmrISG1UVw>? M4nhW2lEPTB;MT60O{DPxE1? NF;xeJkzOzl7OUC0NC=>
T24 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XoeVczKGh? NF;ieJlFVVOR MkLITWM2OD1{LkS0JO69VQ>? MojZNlM6QTlyNEC=
4T1 Mo\YR5l1d3SxeHnjJGF{e2G7 NVGzcZJHPzJiaB?= NFHYOHZFVVOR NGLGNXFKSzVyPUCuNFE3KM7:TR?= M1\QbFI1QDlyNkWy
MCF7 NVe0PYpyS3m2b4TvfIlkKEG|c3H5 NFnCcnM4OiCq Mln1SG1UVw>? M{e1XWlEPTB;MD6wNlcyKM7:TR?= MXGyOFg6ODZ3Mh?=
MCF7 M3XRbmN6fG:2b4jpZ{BCe3OjeR?= NU[0c3MyPzJiaB?= MoSxSG1UVw>? MmfMTWM2OD1yLkCyPVMh|ryP Moe0NlQ5QTB4NUK=
MDA-MB-231 M1ftUmN6fG:2b4jpZ{BCe3OjeR?= MVW3NkBp NHjhO29FVVOR M1jm[2lEPTB;MD6wNlI{KM7:TR?= NHPLfoMzPDh7ME[1Ni=>
MDA-MB-435 NWnRToxvS3m2b4TvfIlkKEG|c3H5 NUe1VVU4PzJiaB?= M{GxRmROW09? MoG2TWM2OD1yLkCwPVch|ryP NX3EZWl6OjR6OUC2OVI>
MDA-MB-468 NGj3dFBEgXSxdH;4bYMhSXO|YYm= MWK3NkBp Ml\xSG1UVw>? NGX3THFKSzVyPUCuNFA3OSEQvF2= MXuyOFg6ODZ3Mh?=
A431 M4\D[WtqdmG|ZTDBd5NigQ>? M3\FfVExKM7:TR?= M1L4NlEhcA>? MkPYSG1UVw>? NEHMUo9KdmirYnn0bY9vKG:oIFXHSnIhf2m2aDDJR|UxKG:oIECuNVczOSEQvF2= MVuyOFg6ODZ3Mh?=
SH-SY5Y Ml\uT4lv[XOnIFHzd4F6 MoKyNVAh|ryP NI[zVmMyKGh? MljESG1UVw>? NF\NeGFKdmirYnn0bY9vKG:oIGDES2ZT[mW2YTD3bZRpKEmFNUCgc4YhOC5yOEOxJO69VQ>? MWSyOFg6ODZ3Mh?=
U251 MojBT4lv[XOnIFHzd4F6 MWmxNEDPxE1? M3\lXVEhcA>? M{DLUGROW09? NUHq[FR3UW6qaXLpeIlwdiCxZjDWSWdHWjJid3n0bEBKSzVyIH;mJFAvODF6OTFOwG0> NGLFc|UzPDh7ME[1Ni=>
Bel7402 NYewd5M{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jZZlczKGh? MmDjSG1UVw>? M1f6U2lEPTB;Mj62O{DPxE1? MlX0NlQ6ODR7NkG=
HK2 NHLPNpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLnS5Y4OiCq Mle3SG1UVw>? MYrJR|UxRTVwOEWg{txO NHu0Uo4zPDlyNEm2NS=>
LO2 M2jTdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlq4O|IhcA>? M1HZ[mROW09? MnvaTWM2OD1zOT65N{DPxE1? M{HKOFI1QTB2OU[x
MV4-11 M4PpRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWG0PEBp MmLwSG1UVw>? MWXJR|UxRTBwMECzJO69VQ>? MWOyOFkxPDl4MR?=
NCI-H3122 M1vEbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDaSYE4OiCq NFnQcZdFVVOR NXPFWldHUUN3ME2wMlg{KM7:TR?= MWCyOFkxPDl4MR?=
NCI-H460 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3TU253PzJiaB?= NYT1XYtJTE2VTx?= NGPnVVlKSzVyPUSuN|Eh|ryP NHzoOlEzPDlyNEm2NS=>
NCI-H526 M{TmTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3uO|IhcA>? NWW0PXBYTE2VTx?= M3;HUmlEPTB;MT6wNUDPxE1? M3ntN|I1QTB2OU[x
TT M1fnRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\Ve|czKGh? M1ntb2ROW09? MoDnTWM2OD1yLkC0JO69VQ>? MXiyOFkxPDl4MR?=
EoL-1-cell MmLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPCSVBKSzVyPUGuOlQheE1? MVjTRW5ITVJ?
MV-4-11 NHTyPW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mke3TWM2OD1{N{KgdG0> NYeyemNpW0GQR1XS
NOS-1 NWfaOWZpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDxR2dKSzVyPUG1MlMhdk1? NIfZV|ZUSU6JRWK=
CGTH-W-1 NV3QdI9GT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;TO4FiUUN3ME2zNE46PCCwTR?= MWfTRW5ITVJ?
MONO-MAC-6 Ml;5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIPGSG5KSzVyPUOzMlghdk1? MkXJV2FPT0WU
ALL-PO Ml7VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDrO2RKSzVyPUe5Mlg6KG6P NX7CeWpuW0GQR1XS
NKM-1 NGPjW4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\ZTWM2OD17OD61NkBvVQ>? NF7xOGNUSU6JRWK=
KM12 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1e2VWlEPTB;M{WwMlE1KG6P M3KwVHNCVkeHUh?=
TE-15 NXzTSFhpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYj6SoZoUUN3ME21NFcvPjFibl2= NXPrTWgyW0GQR1XS
697 M13ueGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTZzND6yOUBvVQ>? MnGxV2FPT0WU
MOLT-16 MoTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zOO2lEPTB;NkOxMlMzKG6P NETZ[YZUSU6JRWK=
GB-1 NFy3UYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7rTZVKSzVyPUexNE4zOyCwTR?= NVjP[o9NW0GQR1XS
TE-12 M4GzSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRThyND61OUBvVQ>? MYrTRW5ITVJ?
ES6 Mnz6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFnPNGpKSzVyPUm4NU4xPiCwTR?= MX7TRW5ITVJ?
LC-2-ad NF;JXphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTFwMUG0NFch|ryP MVfTRW5ITVJ?
BL-70 MoHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjQbpdKSzVyPUGuNVE5PDZizszN NFTlPZZUSU6JRWK=
ETK-1 M{fVZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M33Xd2lEPTB;MT6yPFU5KM7:TR?= MVTTRW5ITVJ?
A4-Fuk M{m5cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7uVXpKSzVyPUGuN|QyPDFizszN NV;3PZRzW0GQR1XS
OCI-AML2 NEfv[nNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTFwM{[4OVEh|ryP M3Py[3NCVkeHUh?=
SIG-M5 MkLPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzKc3pKSzVyPUGuN|cxODlizszN NXTqdGwxW0GQR1XS
NCI-SNU-16 NXjHT|NqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTFwNE[0PFYh|ryP NGLJU2FUSU6JRWK=
PSN1 NEHifWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTFwNUC2O|Yh|ryP MlPpV2FPT0WU
SR NWfWVZpvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHiTWM2OD1zLkW0OVczKM7:TR?= MYHTRW5ITVJ?
A3-KAW NFvXV5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTFwNkK1OFYh|ryP NH\Le3NUSU6JRWK=
KS-1 NFe3NmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NETJSoFKSzVyPUGuOlkzPDdizszN NGjle4ZUSU6JRWK=
CTV-1 NHHFW4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M32xfGlEPTB;MT63Nlc2OSEQvF2= MmLQV2FPT0WU
LB1047-RCC MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml64TWM2OD1zLkixOlI1KM7:TR?= Ml;zV2FPT0WU
EMG-01 NWnIU5lYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{X4cGlEPTB;MT64N|U3OyEQvF2= MVfTRW5ITVJ?
TE-11 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILUTmJKSzVyPUGuPFM6QDVizszN MmP0V2FPT0WU
CMK NWXHeoNFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1HWfGlEPTB;MT65OVUyPyEQvF2= MnzjV2FPT0WU
NB1 M1[5Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFO5T5hKSzVyPUGuPVYyOTdizszN NIThN5NUSU6JRWK=
HAL-01 NV7Dd2l1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjnTWM2OD1{LkC1PVQ3KM7:TR?= M2fzd3NCVkeHUh?=
DEL NYT1OW5nT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DTSGlEPTB;Mj6wPFQ5OiEQvF2= NE\Rc|dUSU6JRWK=
RL95-2 NX7Jd|hOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPMWG1WUUN3ME2yMlEyOTN5IN88US=> MYHTRW5ITVJ?
KARPAS-299 Mli2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTJwMUGzNVMh|ryP NX22XWFuW0GQR1XS
EW-16 NYD5fY1UT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NETKdIVKSzVyPUKuNVM2ODhizszN NYjtWIJpW0GQR1XS
RS4-11 NVHlfHNzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHne4FKSzVyPUKuNVc6OjRizszN M3vRdHNCVkeHUh?=
BB30-HNC Ml7JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{L6XWlEPTB;Mj6yNlM4PSEQvF2= NFSz[YJUSU6JRWK=
DOHH-2 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXLO2JFUUN3ME2yMlM{PDNzIN88US=> MXzTRW5ITVJ?
RPMI-8402 Mli0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHvkbG1KSzVyPUKuN|M3OThizszN MXHTRW5ITVJ?
BV-173 Ml\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2TzPGlEPTB;Mj6zN|Y3KM7:TR?= MlfSV2FPT0WU
TE-10 MmKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGXT[FBKSzVyPUKuN|Q{QDRizszN MXXTRW5ITVJ?
TE-8 NYnPWHZ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHOS4xQUUN3ME2yMlM4ODN6IN88US=> MWrTRW5ITVJ?
K052 NFr5ZolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHCR3JKSzVyPUKuOFAzODJizszN NFTmXpdUSU6JRWK=
KARPAS-45 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFv4[3hKSzVyPUKuOFk1PDZizszN MnnaV2FPT0WU
SK-NEP-1 Ml;zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NETP[HlKSzVyPUKuOlAzOzdizszN MVXTRW5ITVJ?
KGN MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\GTWM2OD1{Lk[wN|M6KM7:TR?= M2rJc3NCVkeHUh?=
ML-2 M1PTVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTJwNkO1NVIh|ryP NF3vb45USU6JRWK=
LAMA-84 NIrpdnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXU[YlHUUN3ME2yMlY6PTR3IN88US=> NWX2VmhmW0GQR1XS
LXF-289 MmnhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTJwN{K5PFkh|ryP MmPNV2FPT0WU
A101D MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV33Zm5NUUN3ME2yMlc5OzB2IN88US=> M13PfnNCVkeHUh?=
KY821 NGnFNYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTJwN{m3OVgh|ryP NVX6XWI3W0GQR1XS
ES4 NHjY[nZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1vnbWlEPTB;Mj64NFYzQCEQvF2= MmDZV2FPT0WU
SCC-3 NU\4[mNQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTJwOEK4PVEh|ryP MYTTRW5ITVJ?
NALM-6 M4PVO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17TUmlEPTB;Mj65NFQ4OyEQvF2= MVjTRW5ITVJ?
BL-41 MnLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITrWFNKSzVyPUKuPVEzOjJizszN NYrIPGk1W0GQR1XS
OPM-2 NF:yc2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\zblJZUUN3ME2zMlA2QTV2IN88US=> NVzaSHI1W0GQR1XS
SF126 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLYUolrUUN3ME2zMlA3OTl6IN88US=> MXjTRW5ITVJ?
BE-13 NVT4cG9HT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2T2NWlEPTB;Mz6yN|EyOSEQvF2= MVzTRW5ITVJ?
SF268 NVfzRo5xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NELueYtKSzVyPUOuN|I5PjlizszN Mn3vV2FPT0WU
MOLT-4 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;wPYp2UUN3ME2zMlM6QDN6IN88US=> M3XJOHNCVkeHUh?=
PF-382 NH25SGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTNwNES1O{DPxE1? MVHTRW5ITVJ?
HEL MoG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\O[XlKSzVyPUOuOFgxODVizszN M1PifHNCVkeHUh?=
RPMI-6666 NEf6dIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2S1[WlEPTB;Mz61OFE4OSEQvF2= NW\EdZdxW0GQR1XS
QIMR-WIL NGHreGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\FS2dKSzVyPUOuOlM{QTFizszN MljvV2FPT0WU
ATN-1 NIHsOVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXuTWM2OD1|Lk[3NVE1KM7:TR?= NVr5NHBrW0GQR1XS
BB49-HNC Mn21S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHCc41KUUN3ME2zMlcxPTB6IN88US=> NHfYcodUSU6JRWK=
HCE-4 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTNwN{i2OFIh|ryP NH\lbXlUSU6JRWK=
SK-LMS-1 NWDyZ5ZIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYS0S5ZGUUN3ME2zMlg{OzN6IN88US=> M3:2NHNCVkeHUh?=
MS-1 MkLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlv0TWM2OD1|LkizO|c5KM7:TR?= MonRV2FPT0WU
JAR NHi4[XhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7ZR3JjUUN3ME2zMlk5QDN{IN88US=> Mom1V2FPT0WU
KE-37 M{PWT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnm0TWM2OD12LkC2NVU5KM7:TR?= M3TsRnNCVkeHUh?=
LB996-RCC NXq2O2dvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4nkSWlEPTB;ND6xNlE3QCEQvF2= MWjTRW5ITVJ?
HH M1jIUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;BTWM2OD12LkKwPVE1KM7:TR?= Ml3jV2FPT0WU
HL-60 NF7EXZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkW3TWM2OD12LkKxNFY2KM7:TR?= NEjLSmlUSU6JRWK=
HOP-62 M2PLd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTRwM{O1NkDPxE1? Mn3sV2FPT0WU
NOMO-1 NIHlS3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2TFdGlEPTB;ND6zN|Y6QSEQvF2= M3XnbXNCVkeHUh?=
DU-4475 MlfjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjmdXlKSzVyPUSuN|Y4OjlizszN M1\KcnNCVkeHUh?=
LC4-1 MmjwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLUcJNJUUN3ME20MlM5ODdizszN NG\hfpBUSU6JRWK=
MC116 NHHSXo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnz1TWM2OD12LkSzNFgyKM7:TR?= Mlz1V2FPT0WU
SW982 NEDicGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTRwNUWzNFch|ryP MoLwV2FPT0WU
SK-N-DZ NVXae3JqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTRwNkewPVkh|ryP M{XPbHNCVkeHUh?=
EW-1 MkK2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nSVWlEPTB;ND62O|kyOSEQvF2= NYjodopFW0GQR1XS
SU-DHL-1 M3nPNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnmwTWM2OD12LkiwNVc1KM7:TR?= MknNV2FPT0WU
L-363 M{Hwcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPYOmNKSzVyPUSuPFA3OjFizszN M{W1dnNCVkeHUh?=
OS-RC-2 Mli4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2roR2lEPTB;ND64O|MyKM7:TR?= NV25[GtoW0GQR1XS
HD-MY-Z NXPhZ4xJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\wN3RFUUN3ME21MlE4OzBzIN88US=> NEH3VlZUSU6JRWK=
MHH-PREB-1 M2\oTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXTVJdyUUN3ME21MlMzOzF{IN88US=> MUHTRW5ITVJ?
HC-1 NVP4eGFRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXjIdZFjUUN3ME21MlQ{OjlzIN88US=> NIj5OVNUSU6JRWK=
SK-MM-2 M{n1fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfxXGxKSzVyPUWuOFc5OiEQvF2= NELpN5ZUSU6JRWK=
SH-4 NX2yT|ZYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPkdZYxUUN3ME21MlQ5OzdizszN NIHHTWpUSU6JRWK=
MHH-CALL-2 NHu5T2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTVwN{[3NVkh|ryP MoDVV2FPT0WU
KG-1 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;HTWM2OD14LkCyPFc5KM7:TR?= MVTTRW5ITVJ?
J-RT3-T3-5 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;WVGlEPTB;Nj6wO|kxQSEQvF2= NVfVR5B6W0GQR1XS
MMAC-SF MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUGxW4Q5UUN3ME22MlExQTR7IN88US=> NUDLVmFYW0GQR1XS
IST-SL2 NH;YdYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX7keWt4UUN3ME22MlEzPTF7IN88US=> NYrMTWdiW0GQR1XS
SW954 Ml3wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\VXXI6UUN3ME22MlI4PTF5IN88US=> NE\Bd4xUSU6JRWK=
HDLM-2 MkHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTZwM{KxNFkh|ryP NHnM[2NUSU6JRWK=
ST486 Ml;yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHQTWM2OD14LkO0O|Eh|ryP NWHJ[FFvW0GQR1XS
DG-75 NH;vTVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjwV49wUUN3ME22MlQ{ODZ7IN88US=> M1ftenNCVkeHUh?=
EW-3 NGq3dHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3mxbWlEPTB;Nj60N|IxPyEQvF2= NIjMbZhUSU6JRWK=
8-MG-BA NXr5TohrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTZwNUG1NFch|ryP M1rhc3NCVkeHUh?=
GT3TKB NY\QVVdmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTZwNkC3OlMh|ryP M1znNXNCVkeHUh?=
KU812 NUThe4o2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInsWVNKSzVyPU[uOlk1OiEQvF2= NE\LV2FUSU6JRWK=
CESS NHjyXWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4TobWlEPTB;Nz6xNFQ{QCEQvF2= NWfv[5lZW0GQR1XS
BC-1 NGrX[nlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn[0TWM2OD15LkK0PFEzKM7:TR?= NF3KUohUSU6JRWK=
MZ1-PC M2Hk[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLHXWhHUUN3ME23MlMxOzh7IN88US=> Mk\NV2FPT0WU
NCI-H82 M1\jZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHaSGpKSzVyPUeuN|c5PSEQvF2= Mo\nV2FPT0WU
NCI-H1355 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXMSFlSUUN3ME23MlQ2QDB2IN88US=> M4XOTXNCVkeHUh?=
RPMI-8226 NXzM[3dpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3jVpA6UUN3ME23MlUxPzN7IN88US=> MWjTRW5ITVJ?
ARH-77 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHX0[5RKSzVyPUeuOVM2QTdizszN M4\XdXNCVkeHUh?=
MN-60 M17oRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG[4W2RKSzVyPUeuOVQxQDhizszN MmfvV2FPT0WU
IMR-5 NWfPTmk{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWTocXkxUUN3ME23NFU1QDd4IN88US=> M{HOe3NCVkeHUh?=
KARPAS-422 MlTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTdwNUeyNFYh|ryP M3y5cnNCVkeHUh?=
CA46 NV74SlRnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTdwNUiwNVIh|ryP MVjTRW5ITVJ?
SJSA-1 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLtN|hKSzVyPUeuOlYxPjFizszN MoO2V2FPT0WU
no-11 NWPUNG9FT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTdwN{e1OVch|ryP NILSWHBUSU6JRWK=
IST-SL1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRThwMEK0NVch|ryP NH3hU4dUSU6JRWK=
NCI-H209 MlPrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFrtXVRKSzVyPUiuNVE3PTJizszN MXzTRW5ITVJ?
TALL-1 NIfid3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DWUGlEPTB;OD6xPFM5PCEQvF2= MX3TRW5ITVJ?
KMOE-2 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXpSm5wUUN3ME24MlE6PDJizszN MXvTRW5ITVJ?
HCC1599 NEPNNmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4XmcmlEPTB;OD6xPVk5PyEQvF2= Mn\uV2FPT0WU
CI-1 NW\5fYhTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRThwMkC0NVEh|ryP MUjTRW5ITVJ?
NCI-H1304 MlnKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRThwMkC2OlEh|ryP MVTTRW5ITVJ?
Daudi MmrvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrrXoRKSzVyPUiuNlM2PDZizszN MkjpV2FPT0WU
CPC-N NUnNNYZvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zxU2lEPTB;OD6yPVE6QSEQvF2= NFryWVRUSU6JRWK=
MC-CAR NHXxWHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRThwM{O1PEDPxE1? M{X5NnNCVkeHUh?=
SW872 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRThwM{S3OVgh|ryP M4PqWnNCVkeHUh?=
OVCAR-4 MnznS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfDZ|ZKSzVyPUiuOVA{PTFizszN NUHNXm16W0GQR1XS
OCUB-M NHjjZYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmTZTWM2OD16LkW2OVA5KM7:TR?= NHe1WJFUSU6JRWK=
SK-PN-DW M3y1Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1m4SGlEPTB;OD62NFk5PSEQvF2= M4jDeHNCVkeHUh?=
NCCIT MmrrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV6yTJdQUUN3ME24MlcyPzR3IN88US=> MonaV2FPT0WU
NCI-H1648 M13M[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\WPIV1UUN3ME25MlE{QDN2IN88US=> NFnqXJlUSU6JRWK=
COR-L279 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHwOHdJUUN3ME25MlM6ODlizszN Mn;JV2FPT0WU
LS-123 MlvVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfYTWM2OD17Lk[4NVYyKM7:TR?= NV7PToxSW0GQR1XS
LP-1 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfnXJJKSzVyPUmuO|gxQDNizszN M1qzfnNCVkeHUh?=
NB13 MmfoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTlwN{m5PVQh|ryP M3;vNXNCVkeHUh?=
ONS-76 Ml\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnoXHFKSzVyPUmuPFExOTZizszN NYjwZpFjW0GQR1XS
VA-ES-BJ NYHL[G1{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NETNZ3RKSzVyPUmuPVk6OzNizszN NX\6fXJKW0GQR1XS
GR-ST NYH1[mZXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWq4VoFEUUN3ME2xNE4zOjB5IN88US=> M1LmRnNCVkeHUh?=
ES1 MlTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTFyLkK5PFQh|ryP MWfTRW5ITVJ?
NB14 Mn\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{m0O2lEPTB;MUCuPVI4PyEQvF2= Mn:5V2FPT0WU
Ramos-2G6-4C10 MlPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTFzLkK2OUDPxE1? MVTTRW5ITVJ?
RXF393 NWLBR2d6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnsemp{UUN3ME2xNU41QDN2IN88US=> NETvPJFUSU6JRWK=
NCI-H2107 NFHjRnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLqTWM2OD1zMT61PVg1KM7:TR?= NVfuSodFW0GQR1XS
K562 Mn;1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLRZpZKSzVyPUGxMlg4ODJizszN M{HPRXNCVkeHUh?=
LOUCY MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1Xj[GlEPTB;MUGuPVg4PSEQvF2= NWDGUlh[W0GQR1XS
TGBC1TKB NHLQPYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHnHXYRKSzVyPUGyMlAxOiEQvF2= NF:z[5JUSU6JRWK=
COLO-320-HSR M3vXZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFftXlFKSzVyPUGyMlE2PjVizszN MojjV2FPT0WU
K5 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{PxUmlEPTB;MUKuNlk5PSEQvF2= NXHIdFhYW0GQR1XS
BC-3 NXnHe|JNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmD5TWM2OD1zMj60OlUyKM7:TR?= MWfTRW5ITVJ?
REH NYnJOFdKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml74TWM2OD1zMj62OFk5KM7:TR?= M1fzbXNCVkeHUh?=
NEC8 NEP6cJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7QTWM2OD1zMj62PFg4KM7:TR?= NV\QdnRDW0GQR1XS
IST-MEL1 NY\QXo5bT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTF{Lki2PVQh|ryP NF7ucpdUSU6JRWK=
NCI-H128 M1KxNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mor4TWM2OD1zMz6wO|I{KM7:TR?= Mly3V2FPT0WU
NCI-H1694 Mm\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTF|LkGxOFQh|ryP NW\S[YkzW0GQR1XS
TGW MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDpTWM2OD1zMz6zNlc3KM7:TR?= M3jFcnNCVkeHUh?=
NCI-SNU-1 MmLoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\4OWlEPTB;MUOuN|Q2KM7:TR?= MV;TRW5ITVJ?
IST-MES1 NILiXmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fBWWlEPTB;MUOuOlczQSEQvF2= M2HPTnNCVkeHUh?=
CTB-1 MnS5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDGdllOUUN3ME2xN{44Ojl2IN88US=> NVP3S5V3W0GQR1XS
HUTU-80 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLwOVJKSzVyPUGzMlc2PzNizszN NWf6NJFmW0GQR1XS
LAN-6 MmXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnucoFoUUN3ME2xOE4zPDV5IN88US=> M2jRTnNCVkeHUh?=
KP-N-YS NXvp[HFPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYDxc|VsUUN3ME2xOE4zQDl2IN88US=> MWLTRW5ITVJ?
CCRF-CEM MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HZOmlEPTB;MUSuOFE3QSEQvF2= NEfZbZBUSU6JRWK=
NCI-H1770 Mk\nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXZeXFYUUN3ME2xOE42OzZ7IN88US=> M1TMbXNCVkeHUh?=
MZ2-MEL MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTF3LkKyOVEh|ryP MkfXV2FPT0WU
COR-L88 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1rCcGlEPTB;MU[uNFAyOiEQvF2= MV3TRW5ITVJ?
LOXIMVI MlWwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\GSG9KSzVyPUG2MlI2PiEQvF2= NWjRVpFpW0GQR1XS
KALS-1 Ml3wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmf1TWM2OD1zNj61PVMyKM7:TR?= M3SxXXNCVkeHUh?=
D-283MED NIrxNZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHS0cFZKSzVyPUG2Mlg1QDlizszN NXTkZnlxW0GQR1XS
NCI-H719 MnnjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTF4LkmxOlEh|ryP Ml;SV2FPT0WU
MLMA M3nmOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4HObWlEPTB;MU[uPVkxPyEQvF2= NVyzO4kxW0GQR1XS
EVSA-T Ml;NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlG2TWM2OD1zNz6wOFg2KM7:TR?= Mkn0V2FPT0WU
SK-N-FI NYrOTXB4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHSeGFZUUN3ME2xO{43QTF|IN88US=> NW\HOWFDW0GQR1XS
NTERA-S-cl-D1 NH\EO3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELqN49KSzVyPUG3Mlg2PzJizszN M2HJR3NCVkeHUh?=
NCI-H1882 NEjYWYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjxUZVjUUN3ME2xO{46QDN2IN88US=> NVjFN5NtW0GQR1XS
A704 M124Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU[1eYxyUUN3ME2xO{46QTB2IN88US=> NXnzSGo5W0GQR1XS
L-428 M1j3[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTF6LkCxOVEh|ryP NXXYeVE3W0GQR1XS
HCC1187 NVzNUVJET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37xNGlEPTB;MUiuNFE5PyEQvF2= MWrTRW5ITVJ?
NCI-H1581 MlHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTF6LkC4OlYh|ryP NV3qXnVlW0GQR1XS
BB65-RCC NGLLOIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M371b2lEPTB;MUiuOFE3OiEQvF2= NGLLVnZUSU6JRWK=
EM-2 M3vHRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXqTWM2OD1zOD61OlczKM7:TR?= MX\TRW5ITVJ?
Raji M2LKSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XydGlEPTB;MUmuPVU3PSEQvF2= NFrFZnZUSU6JRWK=
TE-1 NV3NW29PT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEC0VJlKSzVyPUKwMlQyODRizszN MXPTRW5ITVJ?
SW962 NGP1R4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTJyLkSyPVMh|ryP MmXQV2FPT0WU
MHH-NB-11 NX\EdG9XT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfQWpVKSzVyPUKwMlU2OjFizszN MljRV2FPT0WU
no-10 NIHpS5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXhSJpYUUN3ME2yNU4xOjZ2IN88US=> NF\ibJdUSU6JRWK=
GDM-1 M2T0dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlj6TWM2OD1{MT65OFE1KM7:TR?= MnfIV2FPT0WU
KMS-12-PE MmfVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;vfnZKSzVyPUKyMlI4PCEQvF2= NH6wOpFUSU6JRWK=
NCI-H510A NELtWm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHzUOm1KSzVyPUK0MlEzPzhizszN MnXsV2FPT0WU
ES5 MnLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFfOdJFKSzVyPUK0Mlc{PDlizszN Ml\QV2FPT0WU
JiyoyeP-2003 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2G0SGlEPTB;Mk[uNlc1OiEQvF2= MUfTRW5ITVJ?
NMC-G1 NH7Qd21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTJ5LkG4NlIh|ryP MmjjV2FPT0WU
NCI-H446 NEn3WHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4GwU2lEPTB;MkeuOFk1PiEQvF2= MV;TRW5ITVJ?
NB7 NYPnXplIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoTxTWM2OD1{Nz65NlI6KM7:TR?= NWTGfJF6W0GQR1XS
A388 NUXPbJROT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rvemlEPTB;MkiuNFA4PCEQvF2= MWjTRW5ITVJ?
JVM-2 M1\lcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVr1WolJUUN3ME2yPE4zQDl6IN88US=> NF\SfHhUSU6JRWK=
HT-144 M3;yVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfqflJKSzVyPUK4MlY6KM7:TR?= MoXSV2FPT0WU
NCI-H747 NIrOU3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTJ6LkmxPVUh|ryP NXjtcIdbW0GQR1XS
NCI-H1650 M33Xemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVznSZBGUUN3ME2yPU4xOTd4IN88US=> MlG5V2FPT0WU
EB-3 NFm1TWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGT0UINKSzVyPUK5MlU{ODlizszN M4Hr[HNCVkeHUh?=
KLE NFLiZYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzCXGloUUN3ME2yPU43OTlizszN NGHaN21USU6JRWK=
TK10 M1P6U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvEeoNKSzVyPUOwMlEzPiEQvF2= MWXTRW5ITVJ?
COLO-668 NWfZPGdbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXQTWM2OD1|MD63PVIh|ryP MkDlV2FPT0WU
NCI-H23 MoT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnOc4pKSzVyPUOxMlExPjNizszN MXnTRW5ITVJ?
GOTO MmqwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3K1U2lEPTB;M{GuOlA5PSEQvF2= NICxfXBUSU6JRWK=
MSTO-211H Mnq5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fEO2lEPTB;M{GuPFY4QCEQvF2= MnvHV2FPT0WU
LB831-BLC NIjKWWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTN{LkO4OFMh|ryP NXfkZ5JRW0GQR1XS
SCH NGf0dHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTN{Lki0PFUh|ryP MkLZV2FPT0WU
EHEB M1T1XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVf1VG5UUUN3ME2zOE4yOTl|IN88US=> NXWwOVBKW0GQR1XS
U-266 Mm\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXj[XNKSzVyPUO0MlI4QDFizszN NFjsfWpUSU6JRWK=
EW-11 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHMTWM2OD1|ND60O|I2KM7:TR?= M2K0W3NCVkeHUh?=
TE-9 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{L0UmlEPTB;M{euNFQxOSEQvF2= MW\TRW5ITVJ?
ES3 M4LIXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1n4UmlEPTB;M{euOVAxPCEQvF2= NWfESop{W0GQR1XS
NCI-H2141 M4nhRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDuTWM2OD1|OD6wPFQ{KM7:TR?= NFrIW5dUSU6JRWK=
MPP-89 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vz[WlEPTB;NEKuNFU5PiEQvF2= NHrabJhUSU6JRWK=
SK-MEL-2 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTR{Lk[0NFUh|ryP NYT4WGFlW0GQR1XS
LC-1F NIrwTZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1jkfWlEPTB;NEOuN|Y5OiEQvF2= NHfDV3BUSU6JRWK=
NH-12 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVyzSYdbUUN3ME20N{46OzV7IN88US=> NGXlVpVUSU6JRWK=
RKO NEjNdWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\YdJFKSzVyPUS0MlEzPTJizszN NWTweWFLW0GQR1XS
KM-H2 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;iTWM2OD12ND65OVc4KM7:TR?= M1;lc3NCVkeHUh?=
SK-UT-1 NWL5XFVrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTR7Lki4NlUh|ryP MlrBV2FPT0WU

... Click to View More Cell Line Experimental Data

In vivo Consistent with the substantial and selective inhibition of VEGFR2 or PDGFR phosphorylation and signaling in vivo, Sunitinib (20-80 mg/kg/day) exhibits broad and potent dose-dependent anti-tumor activity against a variety of tumor xenograft models including HT-29, A431, Colo205, H-460, SF763T, C6, A375, or MDA-MB-435. Sunitinib dosing at 80 mg/kg/day for 21 days leads to complete tumor regression in six of eight mice, without tumor re-growing during a 110-day observation period after the end of treatment. Second round of treatment with Sunitinib remains efficacious against tumors that are not fully regressed during the first round of treatment. Sunitinib treatment results in significant decrease in tumor MVD, with ~40% reduction in SF763T glioma tumors. SU11248 treatment results in a complete inhibition of additional tumor growth of luciferase-expressing PC-3M xenografts, despite no reduction in tumor size. [2] Sunitinib treatment (20 mg/kg/day) dramatically suppresses the growth subcutaneous MV4;11 (FLT3-ITD) xenografts and prolongs survival in the FLT3-ITD bone marrow engraftment model. [3]

Protocol

Kinase Assay:[1]
+ Expand

Biochemical Tyrosine Kinase Assays:

IC50 values for Sunitinib against VEGFR2 (Flk-1) and PDGFRβ are determined using glutathione S-transferasefusion proteins containing the complete cytoplasmic domain of the RTK. Biochemical tyrosine kinase assays to quantitate the trans-phosphorylation activity of VEGFR2 (Flk-1) and PDGFRβ are performed in 96-well microtiter plates precoated (20 μg/well in PBS; incubated overnight at 4 °C) with the peptide substrate poly-Glu,Tyr (4:1). Excess protein binding sites are blocked with the addition of 1-5% (w/v) BSA in PBS. Purified GST-fusion proteins are produced in baculovirus-infected insect cells. GST-VEGFR2 and GST-PDGFRβ are then added to the microtiter wells in 2 × concentration kinase dilution buffer consisting of 100 mM HEPES, 50 mM NaCl, 40 μM NaVO4, and 0.02% (w/v) BSA. The final enzyme concentration for GST-VEGFR2 or GST-PDGFRβ is 50 ng/mL. Twenty-five μL of diluted Sunitinib are subsequently added to each reaction well to produce a range of inhibitor concentrations appropriate for each enzyme. The kinase reaction is initiated by the addition of different concentrations of ATP in a solution of MnCl2 so that the final ATP concentrations spanned the Km for the enzyme, and the final concentration of MnCl2 is 10 mM. The plates are incubated for 5-15 minutes at room temperature before stopping the reaction with the addition of EDTA. The plates are then washed three times with TBST. Rabbit polyclonal antiphosphotyrosine antisera are added to the wells at a 1:10,000 dilution in TBST containing 0.5% (w/v) BSA, 0.025% (w/v) nonfat dry milk, and 100 μM NaVO4 and incubated for 1 hour at 37 °C. The plates are then washed three times with TBST, followed by the addition of goat antirabbit antisera conjugated with horseradish peroxidase (1:10,000 dilution in TBST). The plates are incubated for 1 hour at 37 °C and then washed three times with TBST. The amount of phosphotyrosine in each well is quantitated after the addition of 2,2′-azino-di-[3-ethylbenzthiazoline sulfonate] as substrate.
Cell Research:[3]
+ Expand
  • Cell lines: RS4;11, MV4;11, and OC1-AML5
  • Concentrations: Dissolved in DMSO, final concentrations ~10 μM
  • Incubation Time: 24 and 48 hours
  • Method: Cells are starved overnight in medium containing 0.1% FBS prior to addition of Sunitinib and FL (50 ng/mL; FLT3-WT cells only). Proliferation is measured after 48 hours of culture using the Alamar Blue assay or trypan blue cell viability assays. Apoptosis is measured 24 hours after Sunitinib addition by Western blotting to detect cleavage of poly (ADP-ribose) polymerase (PARP) or levels of caspase-3.
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: Female nu/nu mice implanted s.c. with HT-29, A431, Colo205, H-460, SF763T, C6, A375, or MDA-MB-435, and male nu/nu mice bearing luciferase-expressing PC-3M tumors
  • Formulation: Formulated as a carboxymethyl cellulose suspension or as a citrate buffered (pH 3.5) solution
  • Dosages: ~80 mg/kg
  • Administration: Orally once daily
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 15 mg/mL (28.16 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
4% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing.
2mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 532.56
Formula

C22H27FN4O2.C4H6O5

CAS No. 341031-54-7
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03463460 Suspended Thymic Carcinoma Dwight Owen|National Cancer Institute (NCI)|Ohio State University Comprehensive Cancer Center June 19 2018 Phase 2
NCT02761057 Recruiting Stage III Renal Cell Cancer AJCC v7|Stage IV Renal Cell Cancer AJCC v7|Type 1 Papillary Renal Cell Carcinoma|Type 2 Papillary Renal Cell Carcinoma National Cancer Institute (NCI) April 5 2016 Phase 2
NCT02779283 Recruiting Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia OHSU Knight Cancer Institute|National Cancer Institute (NCI) January 13 2016 Phase 1
NCT02465060 Recruiting Advanced Malignant Solid Neoplasm|Bladder Carcinoma|Breast Carcinoma|Cervical Carcinoma|Colon Carcinoma|Colorectal Carcinoma|Endometrial Carcinoma|Esophageal Carcinoma|Gastric Carcinoma|Glioma|Head and Neck Carcinoma|Kidney Carcinoma|Liver and Intrahepatic Bile Duct Carcinoma|Lung Carcinoma|Lymphoma|Malignant Uterine Neoplasm|Melanoma|Ovarian Carcinoma|Pancreatic Carcinoma|Plasma Cell Myeloma|Prostate Carcinoma|Rectal Carcinoma|Recurrent Bladder Carcinoma|Recurrent Breast Carcinoma|Recurrent Cervical Carcinoma|Recurrent Colon Carcinoma|Recurrent Colorectal Carcinoma|Recurrent Esophageal Carcinoma|Recurrent Gastric Carcinoma|Recurrent Glioma|Recurrent Head and Neck Carcinoma|Recurrent Liver Carcinoma|Recurrent Lung Carcinoma|Recurrent Lymphoma|Recurrent Malignant Solid Neoplasm|Recurrent Melanoma|Recurrent Ovarian Carcinoma|Recurrent Pancreatic Carcinoma|Recurrent Plasma Cell Myeloma|Recurrent Prostate Carcinoma|Recurrent Rectal Carcinoma|Recurrent Skin Carcinoma|Recurrent Thyroid Gland Carcinoma|Recurrent Uterine Corpus Carcinoma|Refractory Lymphoma|Refractory Malignant Solid Neoplasm|Refractory Plasma Cell Myeloma|Skin Carcinoma|Thyroid Gland Carcinoma|Uterine Corpus Cancer National Cancer Institute (NCI) August 12 2015 Phase 2
NCT02626754 Terminated Renal Cell Carcinoma vghtpe user|Taipei Veterans General Hospital Taiwan August 12 2015 Phase 2
NCT01835158 Active not recruiting Clear Cell Renal Cell Carcinoma|Metastatic Renal Cell Cancer|Stage III Renal Cell Cancer AJCC v7|Stage IV Renal Cell Cancer AJCC v7 National Cancer Institute (NCI) July 8 2013 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I was wondering that the compound is in its cis or trans form?

  • Answer:

    S1042 Sunitinib Malate is Z form.

  • Question 2:

    What is the difference between Sunitinib Malate(S1042) and Sunitinib(S7781)?

  • Answer:

    S1042 is the Malate salt form of Sunitinib. The biological activities of these two compounds are the same but the solubility of these two compounds in aqueous solvent are different.

PDGFR Signaling Pathway Map

PDGFR Inhibitors with Unique Features

Related PDGFR Products4

Tags: buy Sunitinib Malate | Sunitinib Malate supplier | purchase Sunitinib Malate | Sunitinib Malate cost | Sunitinib Malate manufacturer | order Sunitinib Malate | Sunitinib Malate distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID